A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Recruitment status
Active, not recruiting
clinicaltrials.gov
Participants
963
clinicaltrials.gov
Lead sponsor
Celldex Therapeutics
clinicaltrials.gov
Start date
2024-07-11
clinicaltrials.gov
Number of sites
235
clinicaltrials.gov

Summary
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
clinicaltrials.gov
Acronym
EMBARQ-CSU1
clinicaltrials.gov
Short title
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
clinicaltrials.gov
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)
clinicaltrials.gov

Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Active, not recruiting
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2027-04-01
clinicaltrials.gov
First posted
2024-06-06
clinicaltrials.gov
Registry last updated
2026-03-25
clinicaltrials.gov
Primary completion date
2026-10-01
clinicaltrials.gov
Start date
2024-07-11
clinicaltrials.gov

Actual participants
963
clinicaltrials.gov
Participants
963
clinicaltrials.gov
Participant count basis
Actual
clinicaltrials.gov
Protocol amendments
8
clinicaltrials.gov
Number of sites
235
clinicaltrials.gov

Data monitoring committee
Yes
clinicaltrials.gov
Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Celldex Therapeutics
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT06445023
clinicaltrials.gov
ClinicalTrials.gov ID
NCT06445023
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Parallel groups
Purpose
Treatment
Masking
Quadruple masking
Masked roles
Participants, Care providers, Investigators, Outcome assessors
Sources for study design
clinicaltrials.gov

  1. Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS). The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.

  1. Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.

  2. Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.

  3. Percentage of participants with UAS7 = 0 at Week 12

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.

  4. Percentage of participants with UAS7 ≤ 6 at Week 12

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.

  5. Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants with AAS7 \> 0 at Day 1 who achieved complete control (AAS7 = 0) at Week 12 Angioedema Activity Score over 7 days \[AAS7\] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.

  6. Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS) in participants who did not respond to or did not tolerate omalizumab. The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.

  7. Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12

    Timeframe: From Day 1 (first dose) to Day 85 (Week 12)

    Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12 in participants who did not respond to or did not tolerate omalizumab.

  8. Incidence of Treatment-Emergent Adverse Events

    Timeframe: From Day 1 (first dose) to Day 477 (Week 68)

    Occurrence of treatment emergent adverse events and serious adverse events during the study.

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
18 Years
Healthy volunteers
No

Key Inclusion Criteria:

  1. Males and females, >/= 18 years of age.

  2. Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).

  3. CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:

    1. The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.
    2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.
    3. UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.

  4. Normal blood counts and liver function tests.

  5. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.

  6. Willing and able to complete a daily symptom electronic diary and comply with study visits.

  7. Participants with and without prior biologic experience are eligible.

Key Exclusion Criteria:

  1. Women who are pregnant or nursing.
  2. Chronic urticaria whose predominant manifestation is due to CIndU.
  3. Other diseases associated with urticaria.
  4. Active pruritic skin condition in addition to CSU.
  5. Medical condition that would cause additional risk or interfere with study procedures.
  6. Known HIV, hepatitis B or hepatitis C infection.
  7. Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.
  8. History of anaphylaxis.
  9. Prior treatment with barzolvolimab.

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Sources for eligibility
clinicaltrials.gov

  • Cahaba Dermatology Skin Health CenterBirmingham, United States
  • First OC Dermatology - Fountain ValleyFountain Valley, United States
  • 310 Clinical ResearchInglewood, United States
  • Dermatology Research AssociatesLos Angeles, United States
  • Focus Clinical Research - Los AngelesLos Angeles, United States
  • Cura Clinical ResearchOxnard, United States
  • Allergy and Asthma ConsultantsRedwood City, United States
  • Acclaim Clinical ResearchSan Diego, United States
  • West Dermatology Research CenterSan Diego, United States
  • Therapeutics Clinical ResearchSan Diego, United States
  • Orso Health, Inc.Torrance, United States
  • Integrated Research of Inland, Inc.Upland, United States
  • Western States Clinical Research IncWheat Ridge, United States
  • Encore Medical Research Boynton BeachBoynton Beach, United States
  • Direct Helpers Research CenterHialeah, United States
  • GSI Clinical ResearchMargate, United States
  • International Dermatology Research Inc - MiamiMiami, United States
  • Miami Dade Medical Research Institute, LLCMiami, United States
  • Sarasota Clinical ResearchSarasota, United States
  • GCP Global Clinical Professionals, LLCSt. Petersburg, United States
  • Paradigm Clinical Research BoiseBoise, United States
  • Endeavor HealthSkokie, United States
  • Dawes Fretzin Clinical Research Group-7910 N Shadeland AveIndianapolis, United States
  • DS Research of Kentucky, LLCLouisville, United States
  • Allergy and Asthma Specialists PSCOwensboro, United States

And 210 more, listed on the interactive page.

Sources for sites
clinicaltrials.gov

Other registry identifiers

  • 2024-513208-32-00
Sources for references
clinicaltrials.gov

Related records

Drugs (1)

Lead sponsors (1)

Conditions (1)

Targets (1)